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Protein phosphorylation initiates signal transduction that triggers lymphocyte activation. 
However, other posttranslational modifications may contribute to this process. Here, we 
show that CD28 engagement induced protein arginine methyltransferase activity and 
methylation on arginine of several proteins, including Vav1. Methylation of Vav1 and IL-2 
production were reduced by inhibiting S-adenosyl-L-homocysteine hydrolase, an enzyme 
that regulates cellular transmethylation. Methylated Vav1 was induced in human and mouse 
T cells and selectively localized in the nucleus, which suggested that this form marks a 
nuclear function of Vav1. Our findings uncover a signaling pathway that is controlled by 
CD28 that is likely to be important for T cell activation.
 
TCR stimulation alone is insufficient to drive
full T cell expansion and differentiation; this
limit is overcome by CD28 coengagement that
favors a sequential activation of thousands of
genes (1). CD28 shares some signaling effectors
with the TCR (e.g., Akt, Vav1, Tec/ITK) and
amplifies calcium increase, activation of small
GTPases, and cytoskeletal changes, and thus,
lowers the activation threshold (1). However,
the vast array of immediate and late biologic
responses that are induced by CD28 costimu-
lation suggest that it controls as yet unknown
pathways.
Studies of receptor-mediated lymphocyte
activation revealed mechanisms based on pro-
tein and lipid phosphorylation that promote
gene activation (2). This view may be incom-
plete because other posttranslational modifica-
tions regulate protein functions and gene
expression. For instance, methylation of pro-
teins on arginine (R) by S-adenosylmethionine
(AdoMet)-dependent protein arginine methyl-
transferase (PRMT) may modify protein–protein
and protein–RNA interactions during chromatin
remodeling, transcription, RNA processing,
nuclear import/export, and signal transduction
(3, 4). Mass spectrometry (5, 6), protein mi-
croarrays (7), and anti-R-methylated antibodies
(6) are expanding the list of PRMTs targets
rapidly, and indicate that R-methylation is
more widespread than believed previously.
There are two classes of PRMTs: type I
PRMTs (PRMT 1–4, 6) produce asymmetric
dimethyl-R, whereas type II PRMTs (PRMTs
5, 7) form symmetric dimethyl-R (4). They
differ in target sequences and protein domains
that are likely to confer substrate specificity
and activity regulation (3). Here, we report the
first evidence that an increase of PRMT activity
and R-methylation of several proteins occur
during T cell activation. These events are con-
trolled largely by CD28, and as such, uncover
a novel property of the “second signal” that is
required for T cell activation.
 
RESULTS AND DISCUSSION
CD28-induced an increase of R-methylation 
and protein arginine methyltransferase activity
 
To test whether T cell activation induced
R-methylation of cellular proteins we used an
antimethyl-R antibody (
 
 
 
-Dma). 
 
 
 
-Dma re-
acted in immunoblot (Fig. 1 A, left) and immu-
noprecipitation (Fig. 1 A, middle) with an Arg-
Gly-Gly (RGG)-containing sequence (P3) of
Sam68 (8) after in vitro methylation by glu-
tathione 
 
S
 
-transferase (GST)-PRMT1, assessed
by radioactive labeling (Fig. 1 A, right). 
 
 
 
-Dma
recognized a few proteins in unstimulated pri-
mary T cells by immunoblotting (Fig. 1 B).
Their detection increased at 5 min after super-
antigen (sAg) and B7 costimulation, gradually
rising up to 30 min and several other proteins
(20–120 kD) became visible only after 10–30
min. 
 
 
 
-DMA reactivity decreased toward pro-
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teins of stimulated T cells that were pretreated with the
methyltransferases (MTases) inhibitor, methylthioadenosine
(MTA; Fig. 1 B). These data are reminiscent of nerve
growth factor–treated PC12 cells, where initial R-methyla-
tion was detected at similar times and increased during hours
after stimulation (9). The kinetics of protein R-methylation
is different from tyrosine phosphorylation that is induced
only a few seconds after stimulation (2), and declines after
 
 
 
15–20 min. R-methylation was augmented by B7 stimula-
tion alone and was increased slightly by sAg.
PRMT activity can change in cells that are stimulated by
growth/differentiation factor (9). To determine whether this
was the case during T cell activation, we measured P3 meth-
ylation in lysates of T cells that were stimulated by B7 alone,
or together with sAg. With this assay (Fig. 1 C), we consis-
tently detected basal PRMT activity that increased after
5–10 min of B7 stimulation, and was augmented weakly by
sAg. Longer kinetics showed a small increase at 30 min (un-
published data). To assess the role of CD28 signaling in this
event directly, we used Jurkat cells which expressed CD28
Figure 1. T cell activation increases protein R-methylation and 
PRMT activity. (A) GST-P3 was reacted with or without AdoMet and 
GST-PRMT1 (left), or with or without GST-PRMT1 and AdoMet (middle; see 
Materials and methods) and immunoblotted with  -Dma antibody (left), 
or immunoprecipitated by  -Dma antibody and then immunoblotted with 
 -GST antibody (middle). PRMT1-dependent 3H incorporation in P3 in the 
presence of [3H]-AdoMet (right). Incubation, SDS-PAGE, and blotting were 
as in the left panel. The apparent discrepancy in migration of GST-P3 
between the immunoprecipitate and reaction mixture (middle) was due to 
the use of NuPAGE Bis-Tris/MOPS and Tris-glycine SDS-gels, respectively. 
No 3H was detected in GST. Control for reaction mixture is below each 
experiment. (B) 106 T cells stimulated with 2.5   105 5–3.1-B7 cells 
prepulsed or not with a sAg cocktail (1  g/ml) for the indicated times as 
described in Materials and methods. Lysates were immunoblotted with 
 -Dma (top). Equal loading was controlled by  -Vav1 (bottom). MTA was 
0.3 mM for 1 h before stimulation. Shown is one representative of two 
experiments. (C) PRMT activity was assessed as in A (left) on a lysate of 
2   106 T cells stimulated as in B with 5–3.1-B7 cells prepulsed (white bars) 
or not (black bars) with sAg. Substrate content (GST-P3 arrow, bottom) was 
controlled by  -GST, quantified to normalize radioactivity content (cpm/mm2) 
associated GST-P3. (D) PRMT activity was detected as in C in lysates of 
1.5   106 CD28WT (black bars) or CD28Del30 (white bars) cells stimulated 
0 or 10 min with 5   105 5–3.1-B7 cells. Substrate content was quantified 
as in C. Data are representative of two experiments. 
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wild-type (CD28WT), or a tail deletion mutant (Del30) un-
able to costimulate (10). Fig. 1 D demonstrates that only in-
tact CD28 induces an increase in PRMT activity, whereas
no change over background was seen in CD28Del30 cells.
Although R-methylation of P3 may be due to PRMT1, we
cannot exclude the implication of other PRMTs because
RGGs can be methylated by other PRMTs (7). How
PRMT activity is regulated by extracellular stimuli is un-
known, but PRMTs possess interaction domains and poten-
tial posttranslational modification sites that may serve this
function (3). These data provide evidence for the first time
that CD28, and to a lesser extent the TCR, connects to a
pathway that regulates cellular R-methylation.
 
Induction of Vav1 R-methylation by CD28 engagement
 
We then asked whether known effectors of CD28 signal-
ing (1) were PRMT targets. Thus, detergent lysates of
CD28WT, CD28Del30, and CD28Neg (lacking CD28)
cells were stimulated with 5–3.1-B7 and immunoprecipi-
tated with 
 
 
 
-Dma, followed by immunoblot for these effec-
tors. 
 
 
 
-Dma immunoprecipitated an 
 
 
 
95-kD protein that
reacted with 
 
 
 
-Vav1 antibodies at 
 
 
 
30 min after stimulation
in CD28WT cells, but not in CD28Del30 or CD28Neg
cells (Fig. 2 A). The 95-kD protein recognized by 
 
 
 
-Dma
co-migrated with Vav1 (Fig. 2 B) and was not seen in
 
 
 
-Dma immunoprecipitates from B7-stimulated Vav1-defi-
cient Jurkat (Fig. 2 C). In contrast, Akt, Lck, and Grb2 did
Figure 2.  -Dma detects Vav1 upon CD28 costimulation. (A) CD28WT, 
CD28Del30, and CD28Neg cells (1.5   107) were stimulated with 0.5   107 
5–3.1-B7 ( ), or 5–3.1 ( ) cells for the indicated times. Lysates were 
immunoprecipitated with  -Dma and immunoblotted with  -Vav1. 
Immunoblot for comparable protein content in lysates is shown (bottom). 
This is one representative of five independent experiments. (B) CD28WT 
cells were stimulated as in A for the indicated times. Lysates were immu-
noprecipitated with  -Dma in parallel with   Vav1,  -Lck,  -Grb-2, 
and  -Akt antibodies. Immunoblots were with the indicated antibodies. 
(C) Vav1-deficient Jurkat cells (JVav) and Jurkat cells were stimulated with 
5–3.1 or 5–3.1-B7 cells for the indicated times and lysates were treated 
as in A. Controls for Vav1 were done by  -Vav1 immunoblot (bottom). 
(D) CD28WT and CD28Del30 cell lines (1.5   107) were stimulated with 
0.5  g/ml SEB prepulsed 5–3.1-B7 cells (0.5   107) for the indicated times. 
Lysates were treated as in A and immunoblotted with  -Vav1. (bottom) 
Comparable Vav1 content in lysates. One experiment is shown of two 
giving similar results. (E) 2   107 cultured T cells were pretreated for 1 h 
with 0.3 mM MTA before stimulation with 0.5   107 5–3.1-B7 cells. Cell 
lysates were reacted to  -Dma as in A, followed by  -Vav1 immunoblotting. 
Similar results were obtained in two experiments. (F) CD28WT cells treated 
with or without PP2 (10  M) were stimulated for 3 or 45 min and pro-
cessed as in A. 10  M of PP2 strongly inhibited B7-induced Vav1 tyrosine 
phosphorylation (not depicted). 
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not seem to react with 
 
 
 
-Dma (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20050176/DC1). Be-
cause of closely migrating IgH and L with Lck, Akt, and
Grb-2 (Fig. S1), these experiments were repeated by probing
the immunoblots with horseradish peroxidase-ProtA and by
direct identification of the proteins that were immunopre-
cipitated (Fig. 2 B); it confirmed that Akt, Lck, and Grb2 did
not react with 
 
 
 
-Dma in unstimulated or B7-stimulated
cells. These data suggested that Vav1 was a PRMT target.
 
 
 
-CD28 antibody cross-linking of CD28WT cells, but not
CD28Del30 cells, resulted in Vav1 detection by 
 
 
 
-Dma at
40 min (Fig. S2 A, available at http://www.jem.org/cgi/
content/full/jem.20050176/DC1), and supported a direct
role for CD28 signal in this event. In contrast, Vav1 was de-
tected faintly at the same time point (or before) upon TCR
cross-linking with 
 
 
 
-CD3 antibody (Fig. S2 B). Vav1 signal
detection was 
 
 
 
10-fold less than that of 
 
 
 
-CD28 stimula-
tion (Fig. S2, B and C). The higher capacity of CD28 over
TCR signal to induce detection of Vav1 by 
 
 
 
-Dma was as-
sessed further in a more physiologic setting using 
 
Staphylococ-
cus aureus
 
 enterotoxin B (SEB)-loaded APC stimulation of
CD28WT and CD28Del30 cells (10). Thus, TCR and
CD28 costimulation of CD28WT cells with SEB-loaded
5–3.1-B7 cells (Fig. 2 D), but not of CD28Del30 cells, in-
duced Vav1 recognition by 
 
 
 
-Dma at 40 min. Vav1 was
detected in CD28Del30 cells only at a 20-fold higher SEB
concentration (unpublished data). TCR and CD28 coen-
gagement induced stronger Vav1 detection than CD28 alone
(unpublished data). B7-induced Vav1 detection by 
 
 
 
-Dma
was confirmed in primary T cells (Fig. 2 E), and was inhib-
ited by MTA pretreatment (Fig. 2 E); this is consistent with
it being methylation dependent. Inhibition also was ob-
served after T cell exposure to the Src-protein tyrosine ki-
nase inhibitor, PP2 (Fig. 2 F), which suggested an upstream
control by tyrosine kinases.
Our data indicated that Vav1 is methylated directly on
arginine or that it is bound to an R-methylated protein. To
distinguish between these possibilities, we used a mouse T
cell hybridoma (T 8.1) that overexpresses myc-tagged Vav1.
 
 
 
-Dma immunoprecipitated Vav1 in these cells stimulated
by B7 (Fig. 3 A) with a kinetics similar to human T cells
(Fig. 2). Conversely, Vav1 immunoprecipitated with 
 
 
 
-myc
antibody from B7-stimulated cells was detected by 
 
 
 
-Dma
immunoblot (Fig. 3 B), which indicated that Vav1 was
methylated on arginine. Signals detected in unstimulated
cells of human or mouse origin with 
 
 
 
-Vav1, 
 
 
 
-myc, or
 
 
 
-Dma were not always observed. This might be due to
stimulation by receptors other than CD28 or the metabolic
status of the cells.
Vav1 contains no RGG sequence, a PRMT1 target (7),
but it bears five Arg-Gly sites that also can serve as PRMT1
substrates (8). However, PRMT1-targeted sequences that
are divergent from these have been found (11). Moreover,
PRMT4 (or CARM1) target sequences do not show a clear
consensus (7). Whereas, for other PRMTs, no substrate se-
quence has been defined (12, 13). Recent data indicate that
PRMTs 1–6 can be expressed in T cells (14). The loose pre-
diction of the R-methylation site on Vav1 will require mass
spectrometry and genetic studies for its unambiguous identi-
fication. Together, these data provide strong evidence for
CD28-induced Vav1 R-methylation prevailing over the
TCR signal in triggering this event, similar to global
R-methylation and an increase in PRMT activity.
 
Vav1 R-methylation and IL-2 production depend on 
S-adenosyl-L-homocysteine hydrolase activity
 
Methylation reactions generate S-adenosyl-homocysteine, a
potent feedback inhibitor of all MTases that is eliminated
rapidly by S-adenosyl-L-homocysteine hydrolase (SAHase;
reference 15). Pharmacologic SAHase blockers strongly in-
hibit T cell responses (16). To begin investigating the rela-
tionship between CD28-induced R-methylation and T cell
activation, CD28WT cells (Fig. 4 A) were treated with
MDL28, 842 (MDL), a potent irreversible inhibitor of SAH-
ase, and stimulated with sAg-pulsed B7-bearing cells. Fig. 4
A shows that Vav1 R-methylation decreased with increas-
ing doses of MDL. Similar data were obtained with primary
T cells (Fig. S3, available at http://www.jem.org/cgi/
content/full/jem.20050176/DC1) and agreed with inhibi-
tion of PRMTs by S-adenosyl-homocysteine accumulation
Figure 3. B7 induces R-methylation of Vav1. (A) 1.5   107 T 8.1-Vav1 
cells were stimulated with 0.5   107 DAP3 ( ), or DAP3-B7 ( ) cells for the 
indicated times. Lysates that were immunoprecipitated with  -Dma were 
immunoblotted with  -myc antibody. (B) Same experiment as in A, but 
lysates were immunoprecipitated with  -myc and immunoblotted with 
 -Dma. Controls for Vav1 amounts in  -myc immunoprecipitates are shown 
(bottom). Comparable data were obtained in three other experiments. 
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at MDL concentrations and pretreatment conditions (1 h) that
did not cause cell death (not depicted). MDL inhibits IL-2
production in normal T cells (16), but it was unclear
whether this effect depended on a blockade of early or late
biochemical changes. Therefore, we measured the effect of
MDL on IL-2 production in CD28WT cells instead of pri-
mary T cells, because in the former it only takes 2 h to de-
tect IL-2 after sAg/B7 costimulation (unpublished data).
This allowed us to determine whether MDL inhibition on
IL-2 expression was due to interference with early bio-
chemical events, including R-methylation. Fig. 4 B shows
that MDL decreased IL-2 production at 4 h (and 2 h, not
depicted) after stimulation, within the same range of con-
centrations (1–5 
 
 
 
M) that inhibited Vav1 methylation.
MDL did not reduce tyrosine phosphorylation that was in-
duced by TCR or CD28 signals (Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20050176/DC1). This
suggested that PRMTs do not control early tyrosine phos-
phorylation or that MDL caused no toxic affect on it. No
significant change in SAHase activity upon CD28 stimula-
tion or of protein expression was detected (unpublished
data). Although other MTases—in addition to PRMTs—
may be inhibited by MDL, these data suggest that CD28-
induced R-methylation may be one important event for IL-2
production.
 
Methylated Vav1 segregates within the nuclear fraction
 
Although the CD28-driven increase in PRMT activity and
global R-methylation began within 5 min after stimulation,
Vav1 methylation was detected later (20–30 min; Figs. 1 and
2). Recent data showed that Fc
 
 
 
R stimulation induces a nu-
clear localization sequence (NLS)-dependent Vav1 nuclear ac-
cumulation within 
 
 
 
20 min (17). Because R-methylation
may be required for nuclear residency (3, 8), we wondered
whether R-methylated Vav1 localized in the nucleus. Cyto-
plasmic and nuclear fractions of CD28WT cells that were
stimulated with 5–3.1-B7 cells were immunoprecipitated with
 
 
 
-Vav1, followed by 
 
 
 
-Dma immunoblotting. Fig. 5 A dem-
onstrates that R-methylated Vav1, detected at 30–40 min after
B7 stimulation, localized selectively in the nuclear fraction,
whereas most of the Vav1 immunoprecipitated from the cyto-
sol did not react with 
 
 
 
-Dma. Loading equal amounts of pro-
teins from nuclear and cytoplasm extracts (Fig. 5 B) further
confirmed the presence of Vav1 in the nuclear fraction after
stimulation. Controls for cytoplasmic (ZAP-70) and mito-
chondrial (Hsp60) markers indicated minimal contamination
of cytoplasmic content in the nuclear fraction; Ku70 protein,
which is expressed in both, indicated that the nuclear fraction
was obtained (Fig. 5 B), as confirmed in other experiments us-
ing CDK7 (not depicted). These data, reproduced several
Figure 4. MDL 28, 842 inhibits Vav1 R-methylation and IL-2 pro-
duction. (A) 1.5   107 CD28WT cells were pretreated for 1 h with 0.1 and 
1  M MDL and stimulated for 40 min with 0.5   107 SEB-pulsed 5–3.1-B7 
cells, as in Fig. 2 B. Lysates were processed, immunoprecipitated with 
 -Dma, and Vav1 was detected as in Fig. 2 B. Numbers indicate relative 
amounts of methylated Vav1 signal after normalization for protein (bottom). 
Similar results were obtained in two experiments. (B) 5   105 CD28 WT 
cells (triplicates) were treated for 1 h with 0.1, 1, and 5  M of MDL. After 
washing, they were stimulated for 3.5 h with 105 5–3.1-B7 cells pulsed 
with SEB (0.5  g/ml). Brefeldin A (10  g/ml) was added after 1 h of incu-
bation. Cells were treated as described in Materials and methods for IL-2 
FACS analysis. Similar results were obtained in four experiments.
Figure 5. R-methylated Vav1 localizes in the nuclear fraction. 
(A) CD28WT cells (107) stimulated with 0.3   107 5–3.1-B7 cells for the 
indicated times were processed to obtain cytosol (C) or nuclear (N) proteins. 
 -Vav1 immunoprecipitates from each fraction were immunoblotted with 
 -Dma (top). Vav1 content was controlled after stripping and reprobing 
with  -Vav1 (bottom). (B) 20  g of C and N protein were loaded on SDS-PAGE 
and immunoblotted with indicated antibodies.CD28-INDUCED ARGININE METHYLATION | Blanchet et al. 376
times in Jurkat cells, were confirmed in T8.1–Vav-1 hybrid-
oma (unpublished data). Vav1 R-methylation seemed to be
delayed slightly with respect to Vav1 detection in the nuclear
fraction (Fig. 5 A and not depicted); this suggested that Vav1
migrates into the nucleus where it becomes R-methylated.
Therefore, although increases in PRMT activity may coincide
with R-methylation of some substrates (Fig. 1, B and C), this
modification may require appropriate subcellular localization
for others (e.g., Vav1; reference 3). It is of interest that Itk also
was R-methylated after CD28 costimulation with kinetics
similar to Vav1 (unpublished data).
Vav1 regulates cytoskeleton remodeling, calcium in-
crease, and Erk activation that were detected seconds/min-
utes after TCR/CD28 coligation (1). In contrast, methylated
Vav1 accumulated in the nucleus  30 min after stimulation,
which suggests that this modification marks another function
of Vav1. Nuclear Vav1 seems to associate with NFAT- and
NF- B–containing transcriptional complexes (17), and coac-
tivators can be regulated by R-methylation (14, 18). Future
studies should elucidate whether Vav1 R-methylation is re-
quired for nuclear retention or modulation of transcriptional
activities. Understanding the impact of Vav1 R-methylation
on T cell activation should await mutation analysis of the tar-
get residue(s). However, a few considerations suggest it to
have biologic relevance. Densitometry analysis (Figs. 2 B, 5
A, and not depicted) revealed that R-methylated Vav1 repre-
sents 1–3% of total Vav1, a figure that is similar, for example,
to the levels of TCR-bound phosphorylated ZAP-70 (19)
that is sufficient to trigger T cell activation. Moreover, the
conservation of Vav1 R-methylation in human and mouse
demonstrated here suggests an important function. Because
six ATP molecules are required for each methylation to oc-
cur (20), its functional benefit ought to overbalance this high
energetic cost for it to be conserved in evolution.
The role of R-methylation and PRMTs in the regula-
tion of the immune system is beginning to emerge. CARM1
plays a role in T cell development (21), and PRMT1-medi-
ated R-methylation of the nuclear cofactor Nip45 modulates
cytokine gene expression (14). Our study should raise inter-
est in further understanding the significance of R-methyla-
tion in lymphocyte activation, as we show that this modifi-
cation is induced rapidly upon costimulation and gradually
increases thereafter. Dimethylated-R is a stable protein mod-
ification and no R-dimethylase has been identified to date
(22); this suggests that R-methylation encompasses a signal-
ing time-scale, which is distinct from protein phosphoryla-
tion. R-methylation accumulation during activation may
stabilize gene expression programs or impart long-term
“transcriptional memory” (22) in the differentiating T cell.
One possibility is that CD28-induced R-methylation pro-
vides a more complete explanation for why costimulation
elicits a remarkable series of robust biologic effects (1).
MATERIALS AND METHODS
Cells. CD28WT, CD28Del30, CD28Neg, 5–3.1, and 5–3.1-B7 cells have
been described previously (10). The mouse T cell hybridoma T8.1-Vav1
that overexpresses myc-tagged human Vav1 was from F. Michel (Pasteur In-
stitute, Paris, France). The Vav1-deficient Jurkat cell line JVav (23) was from
R.T. Abraham (The Burnham Institute, La Jolla, California). DAP.3 and
DAP.3-B7 cell lines were obtained from R. Germain (National Institutes of
Health, Bethesda, Maryland). PBMCs stimulated by PHA (2  g/ml) and IL-2
(50 ng/ml; Chiron Corp.) were maintained for 9–11 d before use.
Antibodies, chemicals, and plasmids.  -PhosphoTyr (4G10, UBI);
 -CD28 (CD28.2, Coulter-Beckman);  -KU-70,  -Lck,  -Grb-2, and
 -Akt (Santa Cruz Biotechnology Inc.),  -Itk (2F12, UBI);  -ZAP-70
(Transduction Laboratories),  -Vav1 (Vav30 obtained from J. Griffin, Dana
Farber Cancer Institute, Boston, MA);  -myc (clone 9E10, Roche);  -hIL-2
(BD Biosciences); goat- –mouse IgG1 antibody (SBA);  -mono-dimethyl-
arginine ( -Dma; Abcam);  -GST and  -HSP-60 (Sigma-Aldrich); Staphy-
lococcus enterotoxins (SE)A, B, E and C3 (Toxin Technologies). Z-4 ,5 -
didehydro-5 -deoxy-5 -fluoroadenosine MDL 28,842 was obtained from
G. Zenke (Novartis, Basel, Switzerland). MTA and PP2 were from Sigma-
Aldrich and Calbiochem, respectively. The plasmids, pGEX-GST-P3 (ob-
tained from S. Richard, McGill University, Montreal, Quebec, Canada)
and pGEX-GST (GE Healthcare), were used to obtain GST and GST-P3
by affinity chromatography according to the manufacturer’s instructions.
Cell stimulation and immunoprecipitation. CD28WT, CD28Del30,
and CD28Neg were stimulated with 5–3.1 and 5–3.1-B7 cells with or
without SEB as described previously (10). PHA-blasts, IL-2–starved for 2 d,
were stimulated with 5–3.1-B7 cells pulsed with a cocktail of SEA, SEB,
SEE, and SEC3 (at 1  g/ml each). The T8.1-Vav1 cell line was stimulated
with DAP.3 or DAP.3-B7 as described (24). In some experiments, time 0
was the mix of separate B7-expressing cells and T cells lysates. For IL-2 de-
tection, cells pooled from triplicate wells were fixed with 4% paraformalde-
hyde and permeabilized with 0.5% saponin in PBS/1% BSA.  -huIL-2-PE
(BD Biosciences; 1  g/ml) was added for 30 min, and cells were analyzed
by FACS to detect the percentage of positive cells. Permeabilization and
specificity controls were with  -Bcl-2-PE and isotype-matched irrelevant
IgG1-PE (BD Biosciences), respectively. 0% inhibition was equivalent to
the percentage of positive cells in the absence of MDL. Immunoprecipita-
tion, immunoblots, and chemiluminescence detection and quantification
were as described previously (10).
Subcellular fractionation. Stimulated cells were treated for nuclear and
cytoplasmic extraction using NE-PER kit according to the manufacturer’s
instructions (Pierce Chemical Co.). Proteins were quantified by the Bradford
method (Bio-Rad Laboratories) and subjected to immunoprecipitation after
detergent solubilization. The same concentrations of nuclear and cytoplasmic
proteins were analyzed on SDS-PAGE to control for cross-contamination.
In vitro methylation and protein arginine methyltransferase activity.
GST-PRMT1 (2  g) was reacted for 2 h at 37 C with 5  g of GST or GST-
P3 in 0.5  M S-adenosyl-L-[methyl-3H]methionine in 50  l 25 mM Tris-
HCl, pH 7.4. P3 cold methylation was done with 50  M AdoMet. The reac-
tion was stopped at 100 C for 5 min in SDS-PAGE sample buffer. PRMT
activity was adapted from Cimato et al. (9). Stimulated T cells were subjected
to Dounce homogenization in 50 mM Tris, pH 7.5, with protease inhibitors
on ice. Lysates were incubated with GST or GST-P3–coated glutathione
beads together with 2   Ci [H3]-AdoMet for 1.5 h. After washing, P3-associ-
ated radioactivity (cpm/mm2) was detected after blotting, quantified on a
 -Imager 2000 (Biospace), and normalized to protein content.
Online supplemental material. Fig. S1 shows that Lck, Grb-2, and Akt
are not immunoprecipitated by  -Dma after CD28 engagement. Fig. S2
shows that anti-CD28 triggering induces recognition of Vav1 by  -Dma an-
tibody. Fig. S3 shows that MDL 28, 842 inhibits Vav1 R-methylation in nor-
mal T cells. Fig. S4 shows that MDL 28, 842 does not interfere with activa-
tion-induced tyrosine phosphorylation. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20050176/DC1.JEM VOL. 202, August 1, 2005 377
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